Emakakaela patoloogia 1.

Similar documents
Understanding Your Pap Test Results

Colposcopy. Attila L Major, MD, PhD

Should Anal Pap Smears Be a Standard of Care in HIV Management?

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Histopathology: Cervical HPV and neoplasia

Cervical Cancer : Pap smear

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way

Clinical Practice Guidelines June 2013

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H)

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

The Korean Journal of Cytopathology 13(1): 14-20, 2002

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

BC Cancer Cervix Screening 2015 Program Results. February 2018

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

Int. J. Life. Sci. Scienti. Res., 2(3): (ISSN: ) Impact Factor 2.4 MAY Research Article (Open access)

Tsütoloogia patoloogia osana tänapäeva meditsiinis

Cytology Report Format

Making Sense of Cervical Cancer Screening

Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation

PAP smear. (Papanicolaou Test)

Eradicating Mortality from Cervical Cancer

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology

International Journal of Health Sciences and Research ISSN:

WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1

BCCCP Approved ICD-9 Code List Fiscal Year 2010

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear

The Bethesda System: Updates for th Cytopathology Congress Bursa, Turkey October 14, 2015

GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital

Table of Contents. 1. Overview. 2. Interpretation Guide. 3. Staining Gallery Cases Negative for CINtec PLUS

Chapter 10: Pap Test Results

What is a Pap smear?

Detecting High-Grade Cervical Disease on ASC-H Cytology. Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing

The ABCs of TBS. A Novice's Guide to the Bethesda System

EU guidelines for reporting gynaecological cytology

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)

Cytopathology. Robert M Genta Pathologie Clinique Université de Genève

P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.

NEWER DEVELOPMENTS IN CYTOLOGY

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

CERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb.

Biomed Environ Sci, 2015; 28(1): 80-84

The society for lower genital tract disorders since 1964.

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

Taking Laboratory Coding for a Spin. Corrie Alvarez, CPC, CPMA, CPC-I, CEDC

Becoming a colposcopist: Colposcope case studies

Cervical Dysplasia and HPV

Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure

HPV Testing & Cervical Cancer Screening:

TISSUE TUMOR MARKER EXPRESSION IN

Study of Cervical Pap Smears in a Tertiary Hospital

Comparative Study of Pap Smear and Cervical Biopsy Findings

The LAST Guidelines in Clinical Practice. Implementing Recommendations for p16 Use

Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens

The Bethesda System for Reporting Cervical Cytology: A Historical Perspective

HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests

Prepared By Jocelyn Palao and Layla Faqih

GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED

2016 myresearch Science Internship Program: Laboratory Medicine. Civic Education Office of Government and Community Relations

Kusepõis. Periuretraalne tsoon. Tsentraalne tsoon. Trasitsionaalne tsoon. Eesmine fibromuskulaarne. Perifeerne tsoon. tsoon. Ureetra.

Department of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

Cytomorphologic Features According to HPV DNA Type in Histologically Proven Cases of the Uterine Cervix

European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs

Histopathological Correlation with Cervical Cytology

PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE

Department of Pathology, Kathmandu Medical College & Teaching Hospital, Sinamangal, Kathmandu, Nepal

CINtec p16 INK4a Staining Atlas

A Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

Comparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination

A Study on Diagnostic Accuracy of Cervical Pap Smear by Correlating with Histopathology in a Tertiary Care Centre

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?

Effect of human papillomavirus vaccination on cervical cancer screening in Alberta

Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?

CLINICAL RESEARCH. Background:

Cervical Precancer: Evaluation and Management

L impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du cancer du col uterin

Over-diagnoses in Cytopathology: Is histology the gold standard?

Uterine Cervical Smear Patterns In Females Attending A Teaching Hospital In Rural Eastern Uttar Pradesh, INDIA.

76 Arch Pathol Lab Med Vol 138, January 2014 p16 Utilization in Cervical Biopsies Singh et al

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION

Protocol for an integrated data request of test results from the laboratories of pathological anatomy

Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing

Transformation of Gynaecologic cytology: A Liquid Based Approach

HPV Vaccine Protein L1 Predicts Disease Outcome of High-Risk HPV+ Early Squamous Dysplastic Lesions

National Cervical Screening Program MBS Item Descriptors

ACGME Competency / Milestone Assessment. The Pap Test. Ricardo R. Lastra, MD Zubair W. Baloch, MD, PhD

I have no financial interests in any product I will discuss today.

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

Disclosures Teresa M Darragh, MD

I have no financial interests in any product I will discuss today.

Transcription:

Günekoloogiline patoloogia Emakakaela patoloogia 1. Ave Minajeva

Kirjandus Diane Solomon (Ed), Ritu Nayar. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. Secon edition. Bethesda system web atlas http://nih.techriver.net/

Kirjandust eesti keeles: Minajeva, A. (2007). Inimese papilloomiviirusest tingitud p16 (üle)ekspressiooni immunohistokeemiline hindamine emakakaelavähi ja düsplaasiate diferentsiaaldiagnostikas. Eesti Arst, 86, 266-272.

Cervical cancer incidence and mortality are related to cytological screening

Güneko-tsütoloogilise uuringu tehnika kanal portio üleminekutsoon Ayre spaatel endotserviksi hari

Hari (endotserviks) Ayre spaatel (cul- de- sac) Ayre spaatel (täiustatud)

Cul de sac (kotipõhi) günekoloogilises anatoomias

kahemomentne materjali klaasile kandmine emakakaela portio kanalist, emakaõõnest

Täiustatud Ayre spaatel võimaldab ka ühemomentset materjali pealekandmist

Papanicolaou värving (Pap värving) Multikromaatiline värvimismeetod histoloogilisele ja tsütoloogilisele materjalile. George Papanicolaou: Kaasaegse kliinilise tsütoloogia rajaja. Georgios Nicholas Papanikolaou (George Papanicolaou) 1883-1962

Rakuliigid PAP testis vastavalt anatoomilisele paiknemisele TRANSFORMATSIONI- TSOONIST: METAPLASTILINE LAMEEPITEEL KAELA- KANALIST: SILINDER (NÄÄRME-) EPITEEL PORTIO: LAMEEPITEEL

Endotservikaalne silinderepiteel (cervical columnar epithelium) histoloogiliselt

Histoloogiliselt esineb tupes ja emakakaela tuppe ulatuval osal (nn. portiol) mitmekihiline lameepiteel, millele tsütoloogiliselt vastab 3 liiki rakke: pinnakiht pindmise vahekihi vahekiht sügava kihi rakud. parabasaalkihid basaalkiht süvakiht basaalkiht

Milliseid prekantseroosseid muutusi uuritakse ja kuidas neid klassifitseeritakse?

Emakakaela vähieelsed seisundid Histoloogilised terminid CIN Cervical Intraepithelial Neoplasia CIN 1 = nõrk düsplaasia CIN 2 = mõõdukas düsplaasia CIN 3 = raske düsplaasia ja Carcinoma in situ Tsütoloogilised terminid SIL Squamous Intraepithelial Lesion LSIL - low-grade SIL (vastab CIN1) HSIL (high-grade SIL) = (vastab CIN2 ja CIN3)

Cervical Precancerous States Histology CIN Cervical Intraepithelial Neoplasia CIN 1 = mild dysplasia CIN 2 = modarate dysplasia CIN 3 = severe dysplasia and Carcinoma in situ Cytology SIL Squamous Intraepithelial Lesion LSIL - low-grade SIL (correlated to CIN1) HSIL (high-grade SIL) = (correlated to CIN2 and CIN3)

Kaks süsteemi PAP süsteem Bethesda süsteem loodud 1923 1941 a. Dr. George Papanicolau poolt.koostatud 1988 2001 erialaspetsialistide poolt

The Bethesda System for Cytological Diagnosis Papanicolau stain of cervical smear Specimen adequacy * Description NILM - Negative for Intraepithelial Lesion and Malignancy (PAP I-II) Normal Infections Reactive and reparative cell changes Pathological changes (squamous and columnar epithelium)

Pathological Changes of squamous epithelium in Cytology Changes suggestive of SIL ASC-US - Atypical Squamous Cells of Undetermined Significance ASC-H Atypical Squamous Cells, cannot exclude HSIL SIL Squamous Intraepithelial Lesion LSIL - low-grade SIL HPV related cell changes, mild dysplasia (histologically CIN1) HSIL - high-grade SIL (histologically CIN2 and CIN3) Moderate dysplasia (histologically CIN2) Severe dysplasia (histologically CIN3) Carcinoma in situ Squamous cell carcinoma

PAP klassifikatsioon Bethesda süsteem PAP I PAP II Norm normipärased rakud. reaktiivsete muutustega rakud ASC-US ASC-H üksikud atüüpilised rakud PAP IIIa LGSIL nõrk düsplaasia PAP III PAP IIIb HGSIL mõõdukas düsplaasia tugev düsplaasia PAP IV üksikud vähirakud PAP V emakakaela vähk emakakaela vähk

Emakakaela düspaasia etiopatogenees selle seos erinevate düsplaasia astmetega.

Inimese papilloomiviirus, HPV Emakakaelavähi ja vähieelsete seisundite etioloogiliseks teguriks on HPV viirus (papovaviridae). 1 kaheahelaline DNA molekul (kõik geenid kodeeritakse ühel DNA ahelal)

H P V t ü ü b i d t o i m e HPV madal risk 6, 11, 42 HPV kõrge risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 naha ja limaskesta näsalised vohandid kondüloomid (papilloomid), kerge atüpism limaskestade vähieelsed seisundid vähk Erinevad tüved, mis infitseerivad alumist genitaaltrakti, jagunevad: Madala riskiga HPV tüved - on seotud kondüloomidega ja nõrga düsplaasiaga. Kõrge riskiga HPV tüved - põhjustavad emakakaela rasket düsplaasiat ja invasiivset vähki;

Patogenees

Viirused nakatavad lameepiteeli basaalseid rakke (jagunemisvõimelised rakud). Viirus tungib basaalrakkudeni läbi epiteeli mikroabrasioonide.

LATENTNE FAAS: Viiruskoopiate arv püsib konstantne mitme rakupõlvkonna vältel. Latentses faasis infektsioon võib kliinilselt mitte avalduda.

HPV võib säilitada oma genoomi püsiva ekstrakromosomaalse elemendina rakutuumas episomaalses vormis (madala riskiga HPV tüved):

PRODUKTIIVNE FAAS: Nakatunud rakud liiguvad epiteeli küpsemise käigus pindmistesse kihtidesse. Küpsetes rakkudes algab viiruse vegetatiivne replikatsioon pakitud viiruspartiklid jõuavad koos surnud rakkudega limaskesta pinnale.

Viiruspartiklid elektronmikroskoopiliselt Rakutuumast vabanevad viiruspartiklid lõhustavad tsütoskeletti halo tuuma ümber: koilotsüüt (Kr. tühi).

Kliiniliselt kondüloomid kolposkoopia

Progresseerumine raskeks düsplaasiaks ja vähiks: persisteeruv suure riskiga HPV infektsioon. Viiruse DNA integreerub peremeesraku genoomi.

Viiruse onkoproteiinide ekspressioon E6 E7 p53 inhibeerib prb Tuumorsupressorgeenid

Viiruse onkoproteiinide toime E6 E7 inhibeerib prb Tuumorsupressorgeen inhibeerib P16(INK4a) üleekspressioon Tsükliinsõltuva kinaasi inhibiitor

P16 üleekpressiooni saab raskes düsplaasias ja vähis immunohistokeemiliselt hinnata P16 positiivne värving kattub düsplaasia ulatusega. Mõõdukas düsplaasia (CIN II)

H&E p16 Raske düsplaasia (CINIII): düsplastilised rakud kogu epiteeli paksuses.

H&E p16 Invasiivne vähk

CIN- cervical intraepithelial neoplasia = histoloogiline termin! CIN diagnoos põhineb tuumade atüpismi astmel ja lameepiteeli küpsemise häirumisel ( kaob epiteeli polaarsus) Low-grade madala astme kahjustus: CIN1: sage iseeneslik regressioon, vajalik jälgimine progressiooni suhtes High grade kõrge astme kahjustus (CIN2 ja CIN3): konisatsioon. SIL ja CIN vastavus:

CIN related to SIL

Lameepiteeli düsplaasia astmed: intraepiteliaalne neoplaasia (CIN) histoloogiliselt

CIN 1 puhul sageli epiteeli pindmises kihis HPV infekts tunnused, koilotsütoos, düskeratoos, tuumade hüperkromaasia, hulgituumsed rakud, ebaühtlane tuuma kontuur. Erinevalt HSIL-st säilub epiteeli kihinine küpsemine ning mitoose näeb ainult basaalses/parabasaalses kihis. Düsplastilisi ebaküpseid rakke ainult epiteeli basaalses 1/3. NORM CIN 1

CIN 2 korral võib pinnakihis olla HPV kahjustust ja epiteeli pindmises osas säilub küpsemine. CIN 3 korral mitte. CIN 2-CIN 3. Tuumade tugev atüpism epiteeli süvakihtides. Tuuma/tsütoplasma suhe, hüperkromaasia, tuumade kontuur ebaühtlane. Mitoosid, neid võib leida epiteeli pindmises ½. Võib esineda atüüpilisi mitoose. Rakulise polaarsuse kadumine. CIN 2 Ki 67: mitooside arvu CIN 3

Progression of HPV-induced lesion

HSIL puhul (CIN II-CIN III) emakakaela konisatsioon.

Konisatsioonimaterjal reeglina uuritakse patoloogiliselt täies ulatuses. Võimalusel märgitakse, kas konisaadi lõikepiir düsplaasiavaba

Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Emakakaelakanal, mida kattev metaplastiline lameepiteel on raske düsplaasia tunnustega. Endostervikaalsed näärmed

Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Emakakaelakanal, mida kattev metaplastiline lameepiteel on raske düsplaasia tunnustega. Endostervikaalsed näärmed

Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Endostervikaalsed näärmed Raske düsplaasia: kogu lameepiteeli paksuses atüüpilised rakud, mitoosid

Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Düsplastilised rakud tungimas metaplastilistesse endotservikaalsetesse näärmetesse

Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Raske düsplaasia: kogu lameepiteeli paksuses atüüpilised rakud, mitoosid

CIN 3 hõlmab rasket düsplaasiat ja carcinoma in situ, mõlemad mitteinvasiivset vähieelsed seisundid. Kui olla täpne, siis carcinoma in situ puhul: 1. Puudub rakkude küpsemine kogu epiteeli paksuses. 2. Pindmise kihi rakud võivad olla lamenenud.

Invasiivne kartsinoom

Sarvestuv lamerakk-kartsinoom Mittesarvestuv lamerakk-kartsinoom

Mikropreparaat Gy 43. Emakakaela sarvestuv lamerakuline kartsinoom Normaalne mitmekihiline lameepiteel Sarvestuv lamerakuline kartsinoom: Invasiivne kasv emakakaela stroomasse

Mikropreparaat Gy 43. Emakakaela sarvestuv lamerakuline kartsinoom (G2) Kartsinoomikolded invasiivne kasv: Kollete servas strooma desmoplastiline reaktsioon Atüüpiliste lameepiteelirakkude kollete keskosas sarvestunud rakke

Edaspidi tutvume lähemalt PAP testiga ja näärmeepiteeli muutustega.